{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:19:31Z","timestamp":1769516371121,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Need for parenteral administration and total duration of antibiotic therapy for prosthetic joint infection (PJI) are debated. We report our PJI management, in which outpatient care is privileged.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective multicentre cohort study of PJI managed from January 2017 to Jun 2021. Microbial diagnosis was based on surgical samples. Surgical procedures and antibiotic treatments were reported. Chronic PJI was defined by a course &amp;gt;1 month. Oral antibiotic therapy (OAT) was defined by exclusive use of oral antibiotics or by \u22643 days of parenteral treatments. Management failure was defined by clinical and\/or microbial relapse of PJI over 24 months after surgical treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and seventy-two patients from 13 institutions were included: 103 were male (60%) and mean age was (\u00b1SD): 73\u200a\u00b1\u200a12 years. Sites for PJI were mainly hip (50%) and knee (35%), being chronic infections in 70 cases (41%). The main bacterial genus in monomicrobial infections was Staphylococcus spp. (60%). We recorded 41 (24%) implant exchanges. An OAT was prescribed in 76 cases (44%), and the median (range) course for parenteral route was 6 days (4\u2013180) for 96 cases. Median (range) duration of antimicrobials was 42 days (21\u2013180). Management failure was observed in 7\/76 (9.2%) cases treated with OAT and 15\/96 (15.6%) treated with prolonged parenteral therapy. In multivariate analysis, risk factors for failure were a knee PJI [adjusted OR (95% CI)\u200a=\u200a3.27 (1.27\u20138.40)] and a polymicrobial infection [4.09 (1.46\u201311.49)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>OAT for 6 weeks for PJI was associated with a low rate of management failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad382","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T22:36:05Z","timestamp":1703025365000},"page":"327-333","source":"Crossref","is-referenced-by-count":7,"title":["Prosthetic joint infections: 6 weeks of oral antibiotics results in a low failure rate"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-3093","authenticated-orcid":false,"given":"Pierre-Marie","family":"Roger","sequence":"first","affiliation":[{"name":"Infectiologie, Clinique Les Fleurs, Ave Fr\u00e9d\u00e9ric Mistral , Ollioules , France"},{"name":"Cellule Recherche et Enseignement, Groupe Elsan , Territoire Provence Alpes-C\u00f4te d\u2019Azur, Ollioules , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Assi","sequence":"additional","affiliation":[{"name":"Infectiologie, Clinique Les Fleurs, Ave Fr\u00e9d\u00e9ric Mistral , Ollioules , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Denes","sequence":"additional","affiliation":[{"name":"Infectiologie, Polyclinique de Limoges\u2014Site Ch\u00e9nieux , 18 rue du G\u00e9n\u00e9ral Catroux, Limoges, 87000 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2024020113250515600_dkad382-B1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMra2203477","article-title":"Periprosthetic joint infection","volume":"388","author":"Patel","year":"2023","journal-title":"N Eng J Med"},{"key":"2024020113250515600_dkad382-B2","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s40121-022-00701-0","article-title":"Rates and predictors of treatment failure in Staphylococcus aureus prosthetic joint infections according to different management strategies: a multinational cohort study\u2014the ARTHR-IS study group","volume":"11","author":"Esp\u00edndola","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2024020113250515600_dkad382-B3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/antibiotics10020118","article-title":"Implant removal in the management of prosthetic joint infection by Staphylococcus aureus: outcome and predictors of failure in a large retrospective multicenter study","volume":"10","author":"G\u00f3mez-Junyent","year":"2021","journal-title":"Antibiotics"},{"key":"2024020113250515600_dkad382-B4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2024020113250515600_dkad382-B5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s10096-008-0570-y","article-title":"Adverse effects of parenteral antimicrobial therapy for chronic bone infections","volume":"27","author":"Pulcini","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024020113250515600_dkad382-B6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jbspin.2014.03.021","article-title":"Safety of antibiotics combinations against staphylococcal bone and joint infections","volume":"82","author":"Danr\u00e9","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2024020113250515600_dkad382-B7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/cid\/ciad013","article-title":"Taking on the fundamental questions in infectious diseases two-at-a-time","volume":"76","author":"Gallagher","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024020113250515600_dkad382-B8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10096-009-0842-1","article-title":"Six weeks antibiotic therapy for all bone infections: results of a cohort study","volume":"29","author":"Farhad","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024020113250515600_dkad382-B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomized clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024020113250515600_dkad382-B10","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/jac\/dkz202","article-title":"Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial","volume":"74","author":"Benkabouche","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024020113250515600_dkad382-B11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"2024020113250515600_dkad382-B12","author":"CASFM\/EUCAST"},{"key":"2024020113250515600_dkad382-B13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","article-title":"The dosing and monitoring of vancomycin: what is the best way forward?","volume":"53","author":"Drennan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024020113250515600_dkad382-B14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics11040486","article-title":"Antibiotic therapy for prosthetic joint infections: an overview","volume":"11","author":"Le Vavasseur","year":"2022","journal-title":"Antibiotics"},{"key":"2024020113250515600_dkad382-B15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2024020113250515600_dkad382-B16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.medmal.2020.03.003","article-title":"Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection","volume":"50","author":"Chieffo","year":"2020","journal-title":"Med Mal Infect"},{"key":"2024020113250515600_dkad382-B17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jor.2020.12.021","article-title":"Treatment options in PJI\u2014is two-stage still gold standard?","volume":"23","author":"Lazic","year":"2021","journal-title":"J Orthop"},{"key":"2024020113250515600_dkad382-B18","doi-asserted-by":"crossref","first-page":"ofad246","DOI":"10.1093\/ofid\/ofad246","article-title":"The impact of antimicrobial therapy duration in the treatment of prosthetic joint infections depending on surgical strategies: a systematic review and meta-analysis","volume":"10","author":"Olearo","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024020113250515600_dkad382-B19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmi.2022.08.024","article-title":"Short-course antibiotics for common infections: what do we know and where do we go from here?","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024020113250515600_dkad382-B20","doi-asserted-by":"crossref","first-page":"ofab298","DOI":"10.1093\/ofid\/ofab298","article-title":"Outcome of debridement, antibiotics, and implant retention for staphylococcal hip and knee prosthetic joint infections, focused on rifampicin use: a systematic review and meta-analysis","volume":"8","author":"Scheper","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024020113250515600_dkad382-B21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cmi.2021.10.014","article-title":"How I manage a patient with MRSA bacteraemia","volume":"28","author":"Davis","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024020113250515600_dkad382-B22","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/jac\/dkab271","article-title":"Fully oral targeted antibiotic therapy for Gram-positive cocci-related periprosthetic joint infections: a real-life before and after study","volume":"76","author":"Coehlo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024020113250515600_dkad382-B23","doi-asserted-by":"crossref","first-page":"104739","DOI":"10.1016\/j.idnow.2023.104739","article-title":"Early switching from intravenous to oral antibiotic therapy in bone and joint infections associated with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"53","author":"Petithomme-Nanrocki","year":"2023","journal-title":"Infect Dis Now"},{"key":"2024020113250515600_dkad382-B24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13018-017-0535-x","article-title":"Effect of a standardized treatment regime for infection after osteosynthesis","volume":"12","author":"Hellebrekers","year":"2017","journal-title":"J Orthop Surg Res"},{"key":"2024020113250515600_dkad382-B25","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/327\/56418212\/dkad382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/327\/56418212\/dkad382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:25:27Z","timestamp":1706793927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/2\/327\/7479792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad382","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,19]]}}}